Results 131 to 140 of about 991,087 (297)

Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review

Addiction, EarlyView.
Abstract Background and aims This is the first systematic review of the extant literature on all major psychedelic‐assisted treatment for alcohol use disorder (AUD), tobacco use disorder (TUD) and other substance use disorders (SUD). We aimed to summarise the evidence for efficacy of psychedelic‐assisted treatment for AUD, TUD, and SUD; to evaluate its
Theodore Piper, Francesca Small, Sam Brown, Michael Kelleher, Luke Mitcheson, James Rucker, Allan H. Young, John Marsden   +7 more
wiley   +1 more source

The Transition to Smoking Cessation: Evidence from Multiple Failure Duration Analysis [PDF]

While much is known about the impacts prices and tobacco control policies have on smoking participation and frequency of cigarette use, little is known about their impacts on smoking cessation. This paper addresses the dynamics of smoking cessation using
John A. Tauras
core  

Examining the role of freebase nicotine in the harm reduction potential of oral nicotine pouches versus moist snuff: A randomized crossover trial

Addiction, EarlyView.
Abstract Background and aims Oral nicotine pouches (ONPs) contain varying proportions of freebase nicotine (FBN), with higher FBN expected to increase nicotine delivery across the oral mucosa. Because ONPs contain fewer toxicants than moist snuff and may serve as a reduced harm alternative for smokeless tobacco, we compared how the FBN in ONPs affects ...
Brittney Keller‐Hamilton, Hayley Curran, Leanne Atkinson, Sriya Suraapaneni, Alice Hinton, Kirsten Chrzan, Darren Mays, Ahmad El‐Hellani, Clark W. Wilson, Marielle C. Brinkman, Theodore L. Wagener   +10 more
wiley   +1 more source

Nicotine pouches and clinical outcomes related to smoking cessation: A systematic review of randomized trials

Addiction, EarlyView.
Abstract Background and aims Tobacco‐free nicotine pouches (NPs) are oral nicotine products promoted by manufacturers and some researchers as tools that may reduce nicotine cravings and support smoking reduction or cessation. However, evidence regarding their actual clinical impact remains limited.
Javad Heshmati, Spencer Shahen, Emma Lynn Bates, Sarah Visintini, Evyanne Quirouette, Kerri‐Anne Mullen, Hassan Mir   +6 more
wiley   +1 more source

Exposure to the number of tobacco control policies and tobacco use cessation among adults in Sub-Saharan Africa

, 2018
Background Tobacco use and tobacco-induced diseases are rapidly increasing in Sub-Saharan Africa (SSA). Addressing this problem requires both tobacco use prevention and cessation. This study examined the rate of smoking cessation and assessed effects of
Hadii Mamudu, Abdallah Ibrahim, Ahmed Ouma, Edward Brenya, Rijo John, Daniel Owusu, Liang Wang, Bossman Asare   +7 more
core   +1 more source

‘I'd rather have worse gums than worse lungs’: Young people's views of nicotine pouches in the UK

Addiction, EarlyView.
Abstract Background and aims Nicotine pouches entered the UK market in 2019. Although research has shown that young people's prevalence of use has been low, it has been reported to be increasing and a cause for concern. This paper reports the findings of the first qualitative study in the UK to explore the views of 14–16 year olds' knowledge, awareness
Andy MacGregor, Jessica Shields, Asiya Hamid, Eleanor Holman, Hannah Biggs, Sarah Minty, Jamie Pearce, Allison Ford   +7 more
wiley   +1 more source

Practice-informed implementation: a multi-method approach to map strategies for sustainable tobacco treatment integration within healthcare settings

Frontiers in Health Services
BackgroundTobacco use remains the leading cause of preventable disease and death in the U.S., yet integration of evidence-based tobacco treatment in healthcare is often inconsistent and not sustained.
Katy Ellis Hilts, Jyotsna Gutta, Annette McDaniel, Curtis Williamson, Natalie Rivich, Katelin Rupp, Miranda Spitznagle, Valerie A. Yeager   +7 more
doaj   +1 more source

Varenicline for cannabis use disorder: A randomized controlled trial

Addiction, EarlyView.
Abstract Background and aims Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment‐seeking individuals with CUD ...
Aimee L. McRae‐Clark, Kevin M. Gray, Nathaniel L. Baker, Brian J. Sherman, Bryan Tolliver, Jessica Burt, Alonzo Steplight, Elizabeth Chapman, Amanda Wagner   +8 more
wiley   +1 more source

Determinants of Smoking Cessation: An Analysis of Young Adult Men and Women [PDF]

Substantial econometric efforts have been devoted to examining the impacts prices and tobacco control policies have on smoking propensity and intensity. However, little is known about the effects prices, smoking restrictions, and other influences have on
Frank J. Chaloupka, John A. Tauras
core  

Associations of cannabis use, tobacco use and co‐use with brain volume: A systematic review and meta‐analysis

Addiction, EarlyView.
Abstract Background and aims Cannabis is the most widely used illicit drug worldwide and is often co‐used with tobacco, the leading cause of preventable death. Although cannabis and tobacco have distinct neurobiological actions, their associations with brain volumes are unclear.
Katherine Sawyer, Tom P. Freeman, Martine Skumlien, Esther Walton, Thomas Lancaster, Jorien L. Treur, Valentina Lorenzetti, Anna K. M. Blackwell, Chloe Burke, Richie J. Carr, Constantinos Constantinides, Maisie Cox, Sarah Dance, Shadi Daryan, Sorcha Hamilton, Tom Jenkins, Gemma M. J. Taylor   +16 more
wiley   +1 more source